On May 26, Core Scientific rose 5.03% in pre-market trading, trading at $26.53/share, with trading volume of approximately $1.21 million.

On the news front, the company has recently filed multiple Form 4 and Schedule 13G/A documents in rapid succession, revealing ongoing changes in institutional investor holdings. The market interprets these filings as signaling potential capital inflows, sustaining positive sentiment and pushing the stock further above the analyst target price of $24 previously set by Jefferies.

Within the Application Software sector, computing-power-related names provided additional support. IREN Ltd rose 4.47% and Strategy gained 1.89%, with sector linkage reinforcing Core Scientific's upward momentum. The stock has now extended its recovery well beyond the post-earnings selloff that followed its reported net loss of $347.2 million, which was primarily driven by $266.5 million in non-cash asset impairments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)